SYS-CON MEDIA Authors: Bob Gourley, Sandi Mappic, Eric Brown, RealWire News Distribution, Kevin Benedict

News Feed Item

Global Testosterone Market Report

DUBLIN, April 14, 2014 /PRNewswire/ --

Research and Markets (http://www.researchandmarkets.com/research/fvzl65/global) has announced the addition of the "Global Testosterone Market Report" report to their offering. 
     (Logo: http://photos.prnewswire.com/prnh/20130307/600769 )

The analysts forecast the Global Testosterone market to grow at a CAGR of 26.26 percent over the period 2012-2016. One of the key factors contributing to this market growth is the increasing aging population across the globe. The Global Testosterone market has also been witnessing an increasing number of R&D activities that are focused on developing testosterone replacement therapies. However, the entry of generics could pose a challenge to the growth of this market. 

The report, the Global Testosterone Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market in the Americas and the EMEA and APAC regions; it also covers the Global Testosterone market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Numerous well-known vendors have increased their focus and efforts in R&D toward the development of testosterone replacement products that are more effective, have fewer side effects, and have more potential to enhance testosterone levels. Restoring testosterone levels to normal range improves quality of life in the long term and is beneficial in providing the patient with a range of benefits to his/her muscle and bone and other testosterone-dependent functions. 

Restoring testosterone levels also increases the body-mass index of the patient. Although testosterone replacement therapies replace the hormone in the body, no study has been conducted to see if the same therapy helps reduce the occurrence of fractures and if the therapy would be able to reach a level of clinical significance. 

Thorough investigations have not been conducted to ascertain the threshold serum testosterone level needed to avoid morbidity or its correlation with age. Continuous efforts are being made to explore these arenas, which could lead to the development of new and more effective drugs.

According to the report, one of the main drivers of this market is the increasing global aging population. The number of patients suffering from testosterone deficiency is increasing due to its relatively high prevalence in the elderly population.

Further, the report states that one of the major challenges affecting the market growth is the entry of generic drugs. The introduction of generic drugs will lead to price wars among vendors and to price erosion. The patent expiry of leading brands will also significantly impact the growth of the market during the forecast period. 


Key Topics Covered: 

1. Executive Summary

2. List of Abbreviations

3. Introduction

4. Market Research Methodology

5. Scope of the Report

6. Market Landscape

7. Geographical Segmentation

8. Rate of Incidence and Prevalence

9. Vendor Landscape

10. Buying Criteria

11. Market Growth Drivers

12. Drivers and their Impact

13. Market Challenges

14. Impact of Drivers and Challenges

15. Market Trends

16. Key Vendor Analysis


Companies Mentioned:

  • AbbVie Inc.
  • Acrux Ltd.
  • Actavis Inc.
  • Actient Pharmaceuticals LLC
  • Auxilium Pharmaceuticals Inc.
  • Bayer Schering Pharma AG
  • BioSante Pharmaceuticals Inc.
  • Eli Lilly & Co.
  • Endo Health Solutions Inc.
  • GlaxoSmithKline plc
  • Kyowa Hakko Kirin Co. Ltd.
  • Pfizer Inc.
  • Teva Pharmaceuticals Industries Ltd.
  • Trimel BioPharma SRL.


For more information visit http://www.researchandmarkets.com/research/fvzl65/global


Media Contact: Laura Wood , +353-1-481-1716, [email protected]


More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.